Chardan Capital maintains Buy rating on ProQR Therapeutics, $3 price target
Chardan Capital maintained a Buy rating on ProQR Therapeutics stock with a price target of $3.00, representing an 80.7% upside from the closing price on September 30.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.